Table 2.

Association of 1 mmol/l increase in RLP cholesterol levels with incident NODAT as determined by Cox regression analysis

		All RTR (n = 480)		RTR with IFG excluded (n = 432)
		HR [95% CI]	P value	HR [95% CI]	P value
Model 1	Crude analysis	2.27 [1.64–3.14]	< 0.001	2.21 [1.55, 3.17]	< 0.001
Model 2	Adjusted for age and sex	2.24 [1.62–3.11]	< 0.001	2.18 [1.52, 3.11]	< 0.001
Model 3	Model 2 + BMI, systolic and diastolic blood pressure	1.81 [1.29–2.53]	< 0.001	1.72 [1.18, 2.49]	0.004
Model 4	Model 2 + eGFR and time since transplantation, acute rejection, HLA class I and II antibodies	2.34 [1.63–3.36]	< 0.001	2.0 [1.36, 2.94]	< 0.001
Model 5	Model 2 + UACR	2.23 [1.61, 3.09]	< 0.001	2.17 [1.52, 3.1]	< 0.001
Model 6	Model 2 + plasma glucose, HbA1c	1.80 [1.23–2.64]	0.002	1.72 [1.14, 2.58]	0.009
Model 7	Model 2 + HDL cholesterol, LDL cholesterol	1.68 [1.15–2.47]	0.008	1.65 [1.09, 2.51]	0.019
Model 8	Model 2 + statin use	2.23 [1.59–3.12]	< 0.001	2.09 [1.45, 3.02]	< 0.001
Model 9	Model 2 + smoking and alcohol use	2.33 [1.61, 3.38]	< 0.001	2.2 [1.46, 3.3]	< 0.001
Model 10	Model 2 + use of proliferation inhibitors, calcineurin inhibitors, tacrolimus, cyclosporine and prednisolone dose	2.14 [1.51–3.05]	< 0.001	2.09 [1.42, 3.06]	< 0.001

IFG impaired fasting glucose, BMI body mass index, eGFR estimated glomerular filtration rate, HLA human leukocyte antigen, UACR urinary albumin-to-creatinine ratio, HDL high density lipoprotein, LDL low density lipoprotein